Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies

(2019) Maja J. A. de Jonge et al.   Targeted Oncology

Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors

(2019) Toshihiko Doi et al.   Targeted Oncology

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

(2016) J. C. Soria et al.   ANNALS OF ONCOLOGY

Molecular Pathways: Endothelial Cell FAK--A Target for Cancer Treatment

(2016) M. Roy-Luzarraga et al.   CLINICAL CANCER RESEARCH

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

(2016) Hong Jiang et al.   NATURE MEDICINE

A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors

(2015) Suzanne F. Jones et al.   INVESTIGATIONAL NEW DRUGS

Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer

(2015) Kim N. Chi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

FERM control of FAK function: Implications for cancer therapy

(2014) Ssang-Taek Lim et al.   CELL CYCLE

Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy

(2014) Bernardo Tavora et al.   NATURE

Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth

(2013) Vita M Golubovskaya et al.   BMC CANCER

Playing Russian Roulette With Tyrosine Kinase Inhibitors

(2013) R Z Szmulewitz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The role of FAK in tumor metabolism and therapy

(2013) Jianliang Zhang et al.   PHARMACOLOGY & THERAPEUTICS

A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl) -3, 5, 7-triaza-1-azoniatricyclo [3.3.1.13,7]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo

(2012) V. M. Golubovskaya et al.   CARCINOGENESIS

Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors

(2012) Jeffrey R. Infante et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models

(2010) Colin Walsh et al.   CANCER BIOLOGY & THERAPY

A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High-Fat or Low-Fat Meal in Patients With Advanced Solid Tumors

(2010) E I Heath et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients

(2009) Kevin M. Koch et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271

(2008) W. G. Roberts et al.   CANCER RESEARCH